Organogenesis
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 862
- Market Cap
- -
- Introduction
Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.
Clinical Trials
26
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers
- Conditions
- Diabetic Foot Ulcer
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 170
- Registration Number
- NCT06618612
- Locations
- 🇺🇸
Kent State University, College of Podiatric Medicine, Clevland, Ohio, United States
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients with Osteoarthritis of the Knee
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 474
- Registration Number
- NCT06000410
- Locations
- 🇺🇸
Central Research Associates, Inc., Birmingham, Alabama, United States
🇺🇸Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸Fiel Family & Sports Medicine, Tempe, Arizona, United States
Clinical Study Of Affinity Versus SOC In The Management Of VLUs
- Conditions
- Venous Leg Ulcer
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 200
- Registration Number
- NCT04901013
- Locations
- 🇺🇸
ILD Research, Carlsbad, California, United States
Efficacy of Amniotic Suspension Allograft in Patients with Osteoarthritis of the Knee
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 474
- Registration Number
- NCT04636229
- Locations
- 🇺🇸
Central Research Associates, Birmingham, Alabama, United States
🇺🇸Alabama Clinical Therapeutics, Birmingham, Alabama, United States
🇺🇸AMR Mobile, Mobile, Alabama, United States
Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers
- Conditions
- Diabetic Foot Ulcer
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- Organogenesis
- Target Recruit Count
- 200
- Registration Number
- NCT03855514
- Locations
- 🇺🇸
ILD Research Center, Carlsbad, California, United States
🇺🇸Limb Preservation Platform, Fresno, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
ReNu Shows Promise in Phase 3 Trial for Knee Osteoarthritis
Organogenesis Holdings reports positive interim analysis from its Phase 3 trial of ReNu for knee osteoarthritis, covering 50% of 474 planned patients.